title: Corticotropin-releasing hormone administration increases alpha-melanocyte-stimulating hormone levels in the inferior petrosal sinuses in a subset of patients with Cushing's disease.
abstract: The effect of corticotropin (ACTH)-releasing hormone (CRH) administration on alpha-melanocyte-stimulating hormone (alpha-MSH), ACTH and beta-endorphin (beta-EPH) was evaluated in the inferior petrosal sinuses and in the periphery of 30 patients affected with Cushing's disease subjected to simultaneous and bilateral inferior petrosal sinus sampling for diagnostic purposes. Baseline PRL levels, sensitivity to dexamethasone and surgery outcome were compared to alpha-MSH response. CRH bolus did not modify alpha-MSH concentrations either in the inferior petrosal sinuses or in the periphery in the 30 patients considered as a whole. In 7 of 30 patients, however, a greater than 50% increase over baseline alpha-MSH levels (from 50 to 115.5%) was recorded in the inferior petrosal sinus ipsilateral to the adenoma (from 42.9 +/- 1.7 to 76.4 +/- 4.6 ng/l; p < 0.001), whereas no change was found in the contralateral inferior petrosal sinus or in the periphery. Conversely, as expected, ACTH and beta-ELI significantly increased in all the patients after CRH both in the inferior petrosal sinuses and in the periphery (particularly in the inferior petrosal sinus ipsilateral to the adenoma). No difference in sensitivity to dexamethasone (urinary cortisol percent decrease: 66.4 +/- 4.9 vs. 67.8 +/- 3.4) and surgery outcome (chi 2 test: p = 0.7) was found between patients with alpha-MSH response to CRH and patients without such a response. By contrast, baseline PRL levels, although being normal in both groups, were significantly higher in patients with alpha-MSH response to CRH (18.1 +/- 1.6 vs. 10.1 +/- 0.7 micrograms/l; p < 0.001). In conclusion, the results of the present study suggest that in a subset of patients with Cushing's disease (23.3% of our series) alpha-MSH may be released after the administration of CRH together with ACTH and beta-EPH by adenomatous corticotrophs. In this subset of patients, PRL levels may be in the upper normal range.
authors.affiliation: Department of Molecular and Clinical Endocrinology and Oncology, Università Federico II, School of Medicine, Naples, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: B
authors.initials: B
authors.lastname: Merola
authors.forename: A
authors.initials: A
authors.lastname: Di Sarno
authors.forename: D
authors.initials: D
authors.lastname: Ferone
authors.forename: P
authors.initials: P
authors.lastname: Marzullo
authors.forename: G
authors.initials: G
authors.lastname: Cerbone
authors.forename: F S
authors.initials: FS
authors.lastname: Tripodi
authors.forename: F
authors.initials: F
authors.lastname: Boudouresque
authors.forename: C
authors.initials: C
authors.lastname: Oliver
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
mesh_terms: D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage*; D003480:Cushing Syndrome / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017591:Petrosal Sinus Sampling; D011388:Prolactin / Q000097:blood; D000521:alpha-MSH / Q000378:metabolism*; D001615:beta-Endorphin / Q000097:blood
chemical_list: D000521:alpha-MSH; D001615:beta-Endorphin; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D003346:Corticotropin-Releasing Hormone